Results 201 to 210 of about 735,523 (289)

Neoadjuvant immunotherapy for resectable primary liver cancer (Review). [PDF]

Oncol Lett
Deng Q, He M, Zhang L, Wu Y.
europepmc   +1 more source

Artesunate Nanoplatform Targets the Serine–MAPK Axis in Cancer‐Associated Fibroblasts to Reverse Photothermal Resistance in Triple‐Negative Breast Cancer

Advanced Materials, EarlyView.
The artesunate nanoplatform selectively targets ECM CAF, functioning as a GTPase inhibitor through disruption of intracellular serine homeostasis. This metabolic intervention effectively suppresses MAPK cascade activity, which consequently inhibits PTT‐induced CAF to ECM CAF differentiation.
Dongdong Zheng, Jiaqi Yan, Xuejiao Liu, Zhiming Zhang, Anqi Jin, Yue Zhao, Lu Bai, Mengyao Quan, Xiuzhu Qi, Bin Fu, Zhigang Wu, Jin Zhou, Han Han, Ziqi Wang, Shiyu Wang, Chaoqiang Deng, Weijian Sun, Cai Chang, Shichong Zhou, Hongbo Zhang   +19 more
wiley   +1 more source

Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy. [PDF]

J Nanobiotechnology
Zhu S, Xu W, Li H, Sun Z, Zhu Y, Liu W, Chu H.   +6 more
europepmc   +1 more source

Passive immunotherapy prevents expression of endogenous Moloney virus and amplification of proviral DNA in BALB/Mo mice. [PDF]

, 1980
P. Nobis, Rudolf Jaenisch
openalex   +1 more source

Organic AIE Nanoradiosensitizer Potentiates X‐Ray Triggered Continuous Reactive Oxygen Species Generation for Potent Cancer Radioimmunotherapy

Advanced Materials, EarlyView.
Herein, a glutathione‐responsive system (named THN) is prepared for X‐ray‐triggered sustained ROS generation for efficient antitumor immunotherapy. The double‐promoting ROS generation of THN induced massive immunogenic cancer cell death and polarized M2 macrophages into the M1 phenotype for enhanced antitumor immunotherapy.
Qingyong Xu, Minmin Zhang, Qinqin Huang, Song Gao, Sitong Chu, Qi Li, Wanyao Chen, Xinglong Zhang, Tianfu Zhang, Ben Zhong Tang, Shipeng Ning   +10 more
wiley   +1 more source

Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities. [PDF]

J Exp Clin Cancer Res
Wang H, Niu X, Jin Z, Zhang S, Fan R, Xiao H, Hu SS.   +6 more
europepmc   +1 more source

Adequate Clinical Trials of Immunotherapy [PDF]

, 1982
Kjell Aas
openalex   +1 more source

Self‐Powered α Radionuclide Nanomedicine: Mitochondria‐Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy

Advanced Materials, EarlyView.
A multifunctional nanomedicine co‐loading of the α‐emitter 223RaCl2 within iron‐based MOFs is developed. Precisely targeted to mitochondria, it exploits the full decay spectrum to synchronize three therapeutic actions: direct α‐particle ionization, self‐powered catalytic H2O2 generation via secondary electrons, and immunogenic cell death induction ...
Xian Li, Chaochao Wang, Yelin Wu, Jiajia Zhang, Han Zhang, Shanshan Qin, Linglin Tang, Fei Yu   +7 more
wiley   +1 more source

Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy. [PDF]

Cancer Res Commun
Zhou Z, Cai Y, Yuan H, Chen Q, Zhao SW, Yang J, Liu M, Arreola AX, Ren Y, Xu C, McNally LR, Bronze MS, Houchen CW, Jiang K, Chen WR, Zhang Y, Li M.   +16 more
europepmc   +1 more source

Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. [PDF]

, 1980
H M Jansen, T H Thé, N. G. M. Orie
openalex   +1 more source